Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis

Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy...

Full description

Saved in:
Bibliographic Details
Published inJournal of nuclear cardiology Vol. 30; no. 6; pp. 2464 - 2476
Main Authors Ahluwalia, Nanki, Roshankar, Golnaz, Draycott, Logan, Jimenez-Zepeda, Victor, Fine, Nowell, Chan, Denise, Han, Donghee, Miller, Robert J.H.
Format Journal Article
LanguageEnglish
Published Cham Elsevier Inc 01.12.2023
Springer International Publishing
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1071-3581
1532-6551
1532-6551
DOI10.1007/s12350-023-03297-1

Cover

Abstract Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy. We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling. Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity. Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.
AbstractList Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy. We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling. Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity. Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.
Background Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy. Methods We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling. Results Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity. Conclusions Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.
BackgroundBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.MethodsWe performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.ResultsOut of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.ConclusionsBone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.
Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.BACKGROUNDBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.METHODSWe performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.RESULTSOut of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.CONCLUSIONSBone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.
Author Jimenez-Zepeda, Victor
Roshankar, Golnaz
Draycott, Logan
Fine, Nowell
Ahluwalia, Nanki
Miller, Robert J.H.
Chan, Denise
Han, Donghee
Author_xml – sequence: 1
  givenname: Nanki
  surname: Ahluwalia
  fullname: Ahluwalia, Nanki
  organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada
– sequence: 2
  givenname: Golnaz
  surname: Roshankar
  fullname: Roshankar, Golnaz
  organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada
– sequence: 3
  givenname: Logan
  surname: Draycott
  fullname: Draycott, Logan
  organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada
– sequence: 4
  givenname: Victor
  surname: Jimenez-Zepeda
  fullname: Jimenez-Zepeda, Victor
  organization: Department of Hematology, University of Calgary, Calgary, AB, Canada
– sequence: 5
  givenname: Nowell
  surname: Fine
  fullname: Fine, Nowell
  organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada
– sequence: 6
  givenname: Denise
  surname: Chan
  fullname: Chan, Denise
  organization: Department of Nuclear Medicine, University of Calgary, Calgary, AB, Canada
– sequence: 7
  givenname: Donghee
  surname: Han
  fullname: Han, Donghee
  organization: Departments of Medicine (Division of Artificial Intelligence in Medicine), Imaging and Biomedical Sciences Cedars-Sinai Medical Center, Los Angeles, CA, USA
– sequence: 8
  givenname: Robert J.H.
  surname: Miller
  fullname: Miller, Robert J.H.
  email: robert.miller@albertahealthservices.ca
  organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37226006$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtrFTEYhoNU7EX_gAsJuHEzmttkEnEjbb1AwY2uQyaX05SZ5JhklME_b47TInRxyCIhPM-X8L7n4CSm6AB4idFbjNDwrmBCe9QhQjtEiRw6_ASc4Z6Sjvc9PmlnNOCO9gKfgvNS7hBCkkr5DJzSgRCOED8Df66C3sVUajBQG7NkbVaYPBzbU7CYEGvYZb2_XWGY9S7EHfQpw5p1LPV2za6GCI3ONujmz-uUgk0llPewrKW6WR_mZvcruN9QRwtnV3Wno57WBj0HT72eintxv1-AH5-uv19-6W6-ff56-fGmM4yI2llv-TDyoUdecEG8tm21C4lG4pmwiOGRadZjSYUWmHkp0Mi4NNwLzJ2lF-DNNnef08_FlarmUIybJh1dWooiAksy8J6Khr5-hN6lJbf_HijJGJWIsEa9uqeWcXZW7XMLJ6_qIdYGiA0wOZWSnVcm1JZFii25MCmM1KFBtTWoWoPqX4MKN5U8Uh-mH5XoJpUGx53L_7991PqwWa6F3yrKqhXuonE2ZGeqsikc0_8CRnrCiw
CitedBy_id crossref_primary_10_1016_j_jfma_2024_10_008
crossref_primary_10_1007_s00259_024_06966_6
crossref_primary_10_1007_s00259_023_06576_8
crossref_primary_10_1186_s44348_024_00024_3
crossref_primary_10_1016_j_jmir_2024_02_009
crossref_primary_10_2967_jnumed_123_266926
crossref_primary_10_3390_jcm13030810
crossref_primary_10_1007_s11886_025_02202_1
crossref_primary_10_3390_jcdd11040118
crossref_primary_10_1016_j_jcmg_2023_10_010
crossref_primary_10_1007_s12350_023_03379_0
crossref_primary_10_1016_S2589_7500_24_00024_4
Cites_doi 10.1016/j.hlc.2016.12.017
10.1007/s12350-019-01643-w
10.1177/1536867X0900900203
10.1093/ehjci/jeu107
10.1007/s12350-022-02960-3
10.1007/s00259-010-1642-7
10.1161/CIRCULATIONAHA.116.021612
10.1056/NEJMoa1805689
10.1161/CIRCIMAGING.112.000132
10.1001/jamacardio.2016.2839
10.1007/s12350-019-01753-5
10.1016/j.jcmg.2019.07.015
10.1161/CIRCHEARTFAILURE.119.006075
10.1016/j.jacc.2005.05.073
10.7326/0003-4819-155-8-201110180-00009
10.1186/s13550-021-00828-0
10.3109/13506129.2015.1072089
10.1016/j.jchf.2019.04.010
10.1016/j.jcmg.2020.08.027
10.1186/s41824-018-0035-1
10.1007/s12350-019-01831-8
10.1093/eurheartj/ehab072
10.1007/s12350-016-0610-4
10.1016/j.jcmg.2020.07.043
10.1161/CIRCIMAGING.119.010249
10.1007/s12350-017-0922-z
10.1007/s12350-020-02139-8
10.2967/jnumed.120.247312
10.1016/j.jcmg.2020.03.020
10.1136/bmj.327.7414.557
10.1161/CIRCULATIONAHA.118.035831
10.1016/j.cjca.2019.12.034
10.1093/eurheartj/ehv583
10.1007/s11604-022-01364-0
10.1007/s12350-021-02563-4
10.1007/s12350-022-03180-5
10.1016/j.recesp.2011.12.015
10.1007/s12350-021-02857-7
10.1016/S0735-1097(21)02708-X
10.2967/jnumed.122.264311
10.1007/s12350-021-02880-8
10.1186/s40658-020-00342-7
ContentType Journal Article
Copyright 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.
The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Copyright_xml – notice: 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.
– notice: The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1007/s12350-023-03297-1
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE


ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-6551
EndPage 2476
ExternalDocumentID 37226006
10_1007_s12350_023_03297_1
S1071358124001880
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
--K
-EM
-Y2
.GJ
06D
0R~
0VY
199
1B1
1N0
2.D
203
29L
29~
2JN
2JY
2KG
2LR
2VQ
30V
3V.
4.4
406
408
40D
53G
5GY
5VS
67Z
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
96X
AAAVM
AABHQ
AABYN
AAEDT
AAEOY
AAFGU
AAHNG
AAIAL
AAJKR
AAKSU
AALRI
AANXM
AANZL
AAQFI
AAQXK
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAXUO
AAYFA
AAYIU
AAYQN
AAYTO
AAZMS
ABAKF
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABMAC
ABMQK
ABMYL
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIGE
ACIHN
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACREN
ACTTH
ACUDM
ACVWB
ACWMK
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADMDM
ADMUD
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEEQQ
AEFQL
AEFTE
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETCA
AEVLU
AEVTX
AEXYK
AFAFS
AFBBN
AFKRA
AFLOW
AFNRJ
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGKHE
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AITUG
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
ANMIH
AOCGG
ASPBG
AVWKF
AXYYD
AZFZN
BA0
BBWZM
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
EO8
EO9
ESBYG
EX3
F5P
FDB
FEDTE
FERAY
FFXSO
FGOYB
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYUFA
G-Q
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GRRUI
HF~
HG6
HMCUK
HMJXF
HRMNR
HVGLF
HZ~
IHE
IKXTQ
IMOTQ
ITM
IWAJR
IXC
I~X
J-C
J0Z
J5H
JBSCW
JZLTJ
KOV
KPH
LLZTM
M1P
M41
M4Y
MA-
N2Q
N9A
NAPCQ
NDZJH
NF0
NQ-
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
P19
P2P
P9S
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
R2-
R89
R9I
RHV
RIG
RNI
ROL
RPZ
RSV
RZK
S1Z
S26
S27
S28
S37
S3B
SCLPG
SDE
SDG
SDH
SEW
SHX
SISQX
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
SSZ
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TT1
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
WOW
Z45
Z7U
Z7X
Z7Y
Z82
Z87
ZMTXR
ZOVNA
~A9
AAJBT
AAYZH
ABQSL
ABWVN
ACRPL
ADNMO
AFJKZ
ALIPV
AMRAJ
H13
NPVJJ
SJN
AAYXX
ABFSG
ACSTC
ADHKG
AEZWR
AFHIU
AGCQF
AGQPQ
AHPBZ
AHWEU
AIGII
AIXLP
APXCP
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
EFKBS
K9.
7X8
ID FETCH-LOGICAL-c428t-dfd67b6750f8682fadada7b690b2f48d041b4a451938a814f980b469c6f816ed3
IEDL.DBID AGYKE
ISSN 1071-3581
1532-6551
IngestDate Sun Sep 28 12:16:45 EDT 2025
Wed Aug 13 07:02:44 EDT 2025
Thu Apr 03 07:07:25 EDT 2025
Tue Jul 01 01:28:53 EDT 2025
Thu Apr 24 23:08:02 EDT 2025
Fri Feb 21 02:44:17 EST 2025
Sat Mar 16 16:14:37 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords HCL
HMDP
Meta analysis
SROC
CI
PYP
ATTR-CM
DPD
Amyloid heart disease
SPECT
AUC
Language English
License 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c428t-dfd67b6750f8682fadada7b690b2f48d041b4a451938a814f980b469c6f816ed3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
PMID 37226006
PQID 2894439024
PQPubID 54088
PageCount 13
ParticipantIDs proquest_miscellaneous_2819276538
proquest_journals_2894439024
pubmed_primary_37226006
crossref_citationtrail_10_1007_s12350_023_03297_1
crossref_primary_10_1007_s12350_023_03297_1
springer_journals_10_1007_s12350_023_03297_1
elsevier_sciencedirect_doi_10_1007_s12350_023_03297_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-12-01
PublicationDateYYYYMMDD 2023-12-01
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: United States
– name: New York
PublicationTitle Journal of nuclear cardiology
PublicationTitleAbbrev J. Nucl. Cardiol
PublicationTitleAlternate J Nucl Cardiol
PublicationYear 2023
Publisher Elsevier Inc
Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Elsevier Inc
– name: Springer International Publishing
– name: Springer Nature B.V
References Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022
Witteles, Bokhari, Damy, Elliott, Falk, Fine (bib20) 2019; 7
Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2021.
Galat, Rosso, Guellich, Van Der Gucht, Rappeneau, Bodez (bib36) 2015; 22
Masri, Bukhari, Ahmad, Nieves, Eisele, Follansbee (bib41) 2020; 13
Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (bib9) 2021; 14
Hutt, Quigley, Page, Hall, Burniston, Gopaul (bib35) 2014; 15
Moore, Burrage, Mackenzie, Law, Korczyk, Mollee (bib37) 2017; 26
Ikoma T, Ohtani H, Ohno K, Iguchi K, Suwa K, Sawada M et al. Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol 2022
Harbord, Whiting (bib16) 2009; 9
Bokhari, Morgenstern, Weinberg, Kinkhabwala, Panagiotou, Castano (bib18) 2018; 25
de Haro-del Moral, Sánchez-Lajusticia, Gómez-Bueno, García-Pavía, Salas-Antón, Segovia-Cubero (bib33) 2012; 65
Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021.
Maurer, Bokhari, Damy, Dorbala, Drachman, Fontana (bib8) 2019; 12
Maurer, Schwartz, Gundapaneni, Elliott, Merlini, Waddington-Cruz (bib3) 2018; 379
Dorbala, Ando, Bokhari, Dispenzieri, Falk, Ferrari (bib5) 2021; 14
Watanabe S, Nakajima K, Hiroshi W, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2021
Higgins, Thompson, Deeks, Altman (bib14) 2003; 327
Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Japanese J Radiol 2022
Gillmore, Maurer, Falk, Merlini, Damy, Dispenzieri (bib7) 2016; 133
Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3
Flaherty, Morgenstern, Pozniakoff, DeLuca, Castano, Maurer (bib40) 2020; 27
Tamarappoo, Otaki, Manabe, Hyun, Cantu, Arnson (bib43) 2020; 27
Ben-Haim, Chicheportiche, Goshen, Arad, Smekhov, Menezes (bib26) 2021; 11
Miller RJH, Fine N. Quantifying is believing: techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2021
Bokhari, Castaño, Pozniakoff, Deslisle, Latif, Maurer (bib34) 2013; 6
Whiting, Rutjes, Westwood, Mallett, Deeks, Reitsma (bib13) 2011; 155
Solomon, Adams, Kristen, Grogan, González-Duarte, Maurer (bib17) 2019; 139
Ramsay, Lindsay, Fong, Patford, Younger, Atherton (bib29) 2018; 2
Kessler, Fragoso Costa, Kersting, Jentzen, Weber, Lüdike (bib45) 2023; 30
Garcia-Pavia, Rapezzi, Adler, Arad, Basso, Brucato (bib2) 2021; 42
Coelho, Adams, Conceição, Waddington-Cruz, Schmidt, Buades (bib4) 2020; 15
Dorbala, Cuddy, Falk (bib12) 2020; 13
Dorbala, Park, Cuddy, Singh, Sullivan, Kim (bib25) 2021; 62
Rapezzi, Quarta, Guidalotti, Longhi, Pettinato, Leone (bib32) 2011; 38
Sperry, Burgett, Bybee, McGhie, O’Keefe, Saeed (bib42) 2020; 27
Perugini, Guidalotti, Salvi, Cooke, Pettinato, Riva (bib10) 2005; 46
Bokhari, Castano, Pozniakoff, Deslisle, Latif, Maurer (bib11) 2013; 6
Fontana, Martinez-Naharro, Chacko, Rowczenio, Gilbertson, Whelan (bib31) 2021; 14
Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (bib19) 2021; 14
Scully, Morris, Patel, Treibel, Burniston, Klotz (bib28) 2020; 13
Damy, Costes, Hagège, Donal, Eicher, Slama (bib21) 2015; 37
Gallini, Tutino, Martone, Ciaccio, Costanzo, Taborchi (bib39) 2021; 28
Cappelli, Gallini, Di Mario, Costanzo, Vaggelli, Tutino (bib38) 2019; 26
Castano, Haq, Narotsky, Goldsmith, Weinberg, Morgenstern (bib15) 2016; 1
Fine, Davis, Anderson, Delgado, Giraldeau, Kitchlu (bib1) 2020; 36
Gillmore, Maurer, Falk, Merlini, Damy, Dispenzieri (CR7) 2016; 133
Scully, Morris, Patel, Treibel, Burniston, Klotz (CR28) 2020; 13
Ramsay, Lindsay, Fong, Patford, Younger, Atherton (CR29) 2018; 2
Masri, Bukhari, Ahmad, Nieves, Eisele, Follansbee (CR41) 2020; 13
Cappelli, Gallini, Di Mario, Costanzo, Vaggelli, Tutino (CR38) 2019; 26
Dorbala, Ando, Bokhari, Dispenzieri, Falk, Ferrari (CR5) 2021; 14
de Haro-del Moral, Sánchez-Lajusticia, Gómez-Bueno, García-Pavía, Salas-Antón, Segovia-Cubero (CR33) 2012; 65
Perugini, Guidalotti, Salvi, Cooke, Pettinato, Riva (CR10) 2005; 46
Kessler, Fragoso Costa, Kersting, Jentzen, Weber, Lüdike (CR45) 2023; 30
Rapezzi, Quarta, Guidalotti, Longhi, Pettinato, Leone (CR32) 2011; 38
Castano, Haq, Narotsky, Goldsmith, Weinberg, Morgenstern (CR15) 2016; 1
CR30
Maurer, Schwartz, Gundapaneni, Elliott, Merlini, Waddington-Cruz (CR3) 2018; 379
Solomon, Adams, Kristen, Grogan, González-Duarte, Maurer (CR17) 2019; 139
Moore, Burrage, Mackenzie, Law, Korczyk, Mollee (CR37) 2017; 26
Fontana, Martinez-Naharro, Chacko, Rowczenio, Gilbertson, Whelan (CR31) 2021; 14
Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (CR9) 2021; 14
Galat, Rosso, Guellich, Van Der Gucht, Rappeneau, Bodez (CR36) 2015; 22
Witteles, Bokhari, Damy, Elliott, Falk, Fine (CR20) 2019; 7
Bokhari, Castano, Pozniakoff, Deslisle, Latif, Maurer (CR11) 2013; 6
Ben-Haim, Chicheportiche, Goshen, Arad, Smekhov, Menezes (CR26) 2021; 11
Sperry, Burgett, Bybee, McGhie, O'Keefe, Saeed (CR42) 2020; 27
CR6
Fine, Davis, Anderson, Delgado, Giraldeau, Kitchlu (CR1) 2020; 36
Tamarappoo, Otaki, Manabe, Hyun, Cantu, Arnson (CR43) 2020; 27
Coelho, Adams, Conceição, Waddington-Cruz, Schmidt, Buades (CR4) 2020; 15
CR27
Dorbala, Park, Cuddy, Singh, Sullivan, Kim (CR25) 2021; 62
Bokhari, Morgenstern, Weinberg, Kinkhabwala, Panagiotou, Castano (CR18) 2018; 25
Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (CR19) 2021; 14
Damy, Costes, Hagège, Donal, Eicher, Slama (CR21) 2015; 37
CR24
CR46
CR23
Bokhari, Castaño, Pozniakoff, Deslisle, Latif, Maurer (CR34) 2013; 6
CR22
CR44
Harbord, Whiting (CR16) 2009; 9
Maurer, Bokhari, Damy, Dorbala, Drachman, Fontana (CR8) 2019; 12
Dorbala, Cuddy, Falk (CR12) 2020; 13
Hutt, Quigley, Page, Hall, Burniston, Gopaul (CR35) 2014; 15
Whiting, Rutjes, Westwood, Mallett, Deeks, Reitsma (CR13) 2011; 155
Flaherty, Morgenstern, Pozniakoff, DeLuca, Castano, Maurer (CR40) 2020; 27
Garcia-Pavia, Rapezzi, Adler, Arad, Basso, Brucato (CR2) 2021; 42
Higgins, Thompson, Deeks, Altman (CR14) 2003; 327
Gallini, Tutino, Martone, Ciaccio, Costanzo, Taborchi (CR39) 2021; 28
10.1007/s12350-023-03297-1_bib22
10.1007/s12350-023-03297-1_bib44
10.1007/s12350-023-03297-1_bib23
Ramsay (10.1007/s12350-023-03297-1_bib29) 2018; 2
Maurer (10.1007/s12350-023-03297-1_bib8) 2019; 12
10.1007/s12350-023-03297-1_bib24
Bokhari (10.1007/s12350-023-03297-1_bib34) 2013; 6
10.1007/s12350-023-03297-1_bib46
Poterucha (10.1007/s12350-023-03297-1_bib19) 2021; 14
10.1007/s12350-023-03297-1_bib27
Moore (10.1007/s12350-023-03297-1_bib37) 2017; 26
Dorbala (10.1007/s12350-023-03297-1_bib5) 2021; 14
Witteles (10.1007/s12350-023-03297-1_bib20) 2019; 7
Gallini (10.1007/s12350-023-03297-1_bib39) 2021; 28
Maurer (10.1007/s12350-023-03297-1_bib3) 2018; 379
Galat (10.1007/s12350-023-03297-1_bib36) 2015; 22
Harbord (10.1007/s12350-023-03297-1_bib16) 2009; 9
Bokhari (10.1007/s12350-023-03297-1_bib18) 2018; 25
Bokhari (10.1007/s12350-023-03297-1_bib11) 2013; 6
Castano (10.1007/s12350-023-03297-1_bib15) 2016; 1
de Haro-del Moral (10.1007/s12350-023-03297-1_bib33) 2012; 65
Flaherty (10.1007/s12350-023-03297-1_bib40) 2020; 27
Higgins (10.1007/s12350-023-03297-1_bib14) 2003; 327
Coelho (10.1007/s12350-023-03297-1_bib4) 2020; 15
Fontana (10.1007/s12350-023-03297-1_bib31) 2021; 14
Dorbala (10.1007/s12350-023-03297-1_bib12) 2020; 13
Ben-Haim (10.1007/s12350-023-03297-1_bib26) 2021; 11
Cappelli (10.1007/s12350-023-03297-1_bib38) 2019; 26
Garcia-Pavia (10.1007/s12350-023-03297-1_bib2) 2021; 42
Kessler (10.1007/s12350-023-03297-1_bib45) 2023; 30
Gillmore (10.1007/s12350-023-03297-1_bib7) 2016; 133
Poterucha (10.1007/s12350-023-03297-1_bib9) 2021; 14
Rapezzi (10.1007/s12350-023-03297-1_bib32) 2011; 38
Perugini (10.1007/s12350-023-03297-1_bib10) 2005; 46
Masri (10.1007/s12350-023-03297-1_bib41) 2020; 13
Dorbala (10.1007/s12350-023-03297-1_bib25) 2021; 62
Damy (10.1007/s12350-023-03297-1_bib21) 2015; 37
10.1007/s12350-023-03297-1_bib30
Scully (10.1007/s12350-023-03297-1_bib28) 2020; 13
Whiting (10.1007/s12350-023-03297-1_bib13) 2011; 155
Tamarappoo (10.1007/s12350-023-03297-1_bib43) 2020; 27
Solomon (10.1007/s12350-023-03297-1_bib17) 2019; 139
Sperry (10.1007/s12350-023-03297-1_bib42) 2020; 27
Fine (10.1007/s12350-023-03297-1_bib1) 2020; 36
10.1007/s12350-023-03297-1_bib6
Hutt (10.1007/s12350-023-03297-1_bib35) 2014; 15
References_xml – volume: 379
  start-page: 1007
  year: 2018
  end-page: 1016
  ident: bib3
  article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy
  publication-title: N Engl J Med
– volume: 133
  start-page: 2404
  year: 2016
  end-page: 2412
  ident: bib7
  article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
  publication-title: Circulation
– reference: Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Japanese J Radiol 2022
– reference: Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022
– volume: 14
  start-page: 1221
  year: 2021
  end-page: 1231
  ident: bib9
  article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution
  publication-title: JACC Cardiovasc Imaging
– volume: 6
  start-page: 195
  year: 2013
  end-page: 201
  ident: bib34
  article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
– volume: 6
  start-page: 195
  year: 2013
  end-page: 201
  ident: bib11
  article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
– volume: 327
  start-page: 557
  year: 2003
  end-page: 560
  ident: bib14
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
– volume: 139
  start-page: 431
  year: 2019
  end-page: 443
  ident: bib17
  article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis
  publication-title: Circulation
– reference: Watanabe S, Nakajima K, Hiroshi W, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2021
– reference: Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021.
– volume: 30
  start-page: 101
  year: 2023
  end-page: 111
  ident: bib45
  article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis
  publication-title: J Nucl Cardiol
– reference: Ikoma T, Ohtani H, Ohno K, Iguchi K, Suwa K, Sawada M et al. Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol 2022
– volume: 14
  start-page: 1221
  year: 2021
  end-page: 1231
  ident: bib19
  article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate
  publication-title: JACC
– volume: 2
  start-page: 17
  year: 2018
  ident: bib29
  article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population
  publication-title: Eur J Hybrid Imaging
– volume: 13
  start-page: 1353
  year: 2020
  end-page: 1363
  ident: bib28
  article-title: DPD quantification in cardiac amyloidosis
  publication-title: JACC Cardiovasc Imaging
– volume: 155
  start-page: 529
  year: 2011
  end-page: 536
  ident: bib13
  article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
  publication-title: Ann Intern Med
– volume: 12
  year: 2019
  ident: bib8
  article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Heart Fail
– volume: 15
  start-page: 179
  year: 2020
  ident: bib4
  article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
  publication-title: J Rare Dis
– volume: 42
  start-page: 1554
  year: 2021
  end-page: 1568
  ident: bib2
  article-title: Diagnosis and treatment of cardiac amyloidosis
  publication-title: Eur Heart J
– volume: 27
  start-page: 1802
  year: 2020
  end-page: 1807
  ident: bib42
  article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT
  publication-title: J Nucl Cardiol
– volume: 62
  start-page: 716
  year: 2021
  end-page: 722
  ident: bib25
  article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT
  publication-title: J Nucl Med
– volume: 14
  year: 2021
  ident: bib5
  article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging
  publication-title: Circ Cardiovasc Imaging
– volume: 11
  start-page: 86
  year: 2021
  ident: bib26
  article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis
  publication-title: EJNMMI Res
– volume: 27
  start-page: 28
  year: 2020
  end-page: 37
  ident: bib43
  article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis
  publication-title: J Nucl Cardiol
– volume: 37
  start-page: 1826
  year: 2015
  end-page: 1834
  ident: bib21
  article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
  publication-title: Eur Heart J
– volume: 38
  start-page: 470
  year: 2011
  end-page: 478
  ident: bib32
  article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 1
  start-page: 880
  year: 2016
  end-page: 889
  ident: bib15
  article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging
  publication-title: JAMA Cardiol
– volume: 36
  start-page: 322
  year: 2020
  end-page: 334
  ident: bib1
  article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis
  publication-title: Can J Cardiol
– volume: 14
  start-page: 189
  year: 2021
  end-page: 199
  ident: bib31
  article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression
  publication-title: JACC Cardiovasc Imaging
– reference: Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2021.
– reference: Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3
– volume: 22
  start-page: 210
  year: 2015
  end-page: 220
  ident: bib36
  article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis
  publication-title: Amyloid
– volume: 46
  start-page: 1076
  year: 2005
  end-page: 1084
  ident: bib10
  article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy
  publication-title: J Am Coll Cardiol
– volume: 13
  start-page: 1368
  year: 2020
  end-page: 1383
  ident: bib12
  article-title: How to image cardiac amyloidosis: a practical approach
  publication-title: JACC Cardiovasc Imaging
– volume: 26
  start-page: 497
  year: 2019
  end-page: 504
  ident: bib38
  article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
– volume: 9
  start-page: 211
  year: 2009
  end-page: 229
  ident: bib16
  article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression
  publication-title: STATA J
– volume: 27
  start-page: 371
  year: 2020
  end-page: 380
  ident: bib40
  article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
– volume: 65
  start-page: 440
  year: 2012
  end-page: 446
  ident: bib33
  article-title: Role of cardiac scintigraphy with
  publication-title: Rev Esp Cardiol
– volume: 26
  start-page: 1183
  year: 2017
  end-page: 1190
  ident: bib37
  article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis
  publication-title: Heart Lung Circ
– reference: Miller RJH, Fine N. Quantifying is believing: techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2021
– volume: 13
  year: 2020
  ident: bib41
  article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Cardiovasc Imaging
– volume: 7
  start-page: 709
  year: 2019
  end-page: 716
  ident: bib20
  article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice
  publication-title: JACC Heart Fail
– volume: 15
  start-page: 1289
  year: 2014
  end-page: 1298
  ident: bib35
  article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis
  publication-title: Eur Heart J Cardiovasc Imaging
– volume: 25
  start-page: 181
  year: 2018
  end-page: 190
  ident: bib18
  article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis
  publication-title: J Nucl Cardiol
– volume: 28
  start-page: 90
  year: 2021
  end-page: 99
  ident: bib39
  article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy
  publication-title: J Nucl Cardiol
– ident: CR22
– volume: 26
  start-page: 1183
  year: 2017
  end-page: 1190
  ident: CR37
  article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis
  publication-title: Heart Lung Circ
  doi: 10.1016/j.hlc.2016.12.017
– volume: 28
  start-page: 90
  year: 2021
  end-page: 99
  ident: CR39
  article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01643-w
– volume: 9
  start-page: 211
  year: 2009
  end-page: 229
  ident: CR16
  article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression
  publication-title: STATA J
  doi: 10.1177/1536867X0900900203
– volume: 15
  start-page: 1289
  year: 2014
  end-page: 1298
  ident: CR35
  article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis
  publication-title: Eur Heart J Cardiovasc Imaging
  doi: 10.1093/ehjci/jeu107
– volume: 30
  start-page: 101
  year: 2023
  end-page: 111
  ident: CR45
  article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-022-02960-3
– volume: 38
  start-page: 470
  year: 2011
  end-page: 478
  ident: CR32
  article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1642-7
– volume: 133
  start-page: 2404
  year: 2016
  end-page: 2412
  ident: CR7
  article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.116.021612
– volume: 379
  start-page: 1007
  year: 2018
  end-page: 1016
  ident: CR3
  article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1805689
– volume: 6
  start-page: 195
  year: 2013
  end-page: 201
  ident: CR11
  article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.112.000132
– volume: 14
  start-page: 1221
  year: 2021
  end-page: 1231
  ident: CR19
  article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate
  publication-title: JACC
– ident: CR30
– volume: 1
  start-page: 880
  year: 2016
  end-page: 889
  ident: CR15
  article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2016.2839
– volume: 27
  start-page: 28
  year: 2020
  end-page: 37
  ident: CR43
  article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01753-5
– volume: 13
  start-page: 1368
  year: 2020
  end-page: 1383
  ident: CR12
  article-title: How to image cardiac amyloidosis: a practical approach
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2019.07.015
– volume: 12
  year: 2019
  ident: CR8
  article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Heart Fail
  doi: 10.1161/CIRCHEARTFAILURE.119.006075
– volume: 46
  start-page: 1076
  year: 2005
  end-page: 1084
  ident: CR10
  article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2005.05.073
– volume: 155
  start-page: 529
  year: 2011
  end-page: 536
  ident: CR13
  article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-155-8-201110180-00009
– ident: CR6
– volume: 11
  start-page: 86
  year: 2021
  ident: CR26
  article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis
  publication-title: EJNMMI Res
  doi: 10.1186/s13550-021-00828-0
– ident: CR27
– volume: 22
  start-page: 210
  year: 2015
  end-page: 220
  ident: CR36
  article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis
  publication-title: Amyloid
  doi: 10.3109/13506129.2015.1072089
– volume: 7
  start-page: 709
  year: 2019
  end-page: 716
  ident: CR20
  article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice
  publication-title: JACC Heart Fail
  doi: 10.1016/j.jchf.2019.04.010
– ident: CR23
– volume: 14
  start-page: 1221
  year: 2021
  end-page: 1231
  ident: CR9
  article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.08.027
– volume: 2
  start-page: 17
  year: 2018
  ident: CR29
  article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population
  publication-title: Eur J Hybrid Imaging
  doi: 10.1186/s41824-018-0035-1
– volume: 27
  start-page: 371
  year: 2020
  end-page: 380
  ident: CR40
  article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01831-8
– ident: CR46
– volume: 42
  start-page: 1554
  year: 2021
  end-page: 1568
  ident: CR2
  article-title: Diagnosis and treatment of cardiac amyloidosis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab072
– volume: 25
  start-page: 181
  year: 2018
  end-page: 190
  ident: CR18
  article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-016-0610-4
– volume: 14
  start-page: 189
  year: 2021
  end-page: 199
  ident: CR31
  article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.07.043
– volume: 13
  year: 2020
  ident: CR41
  article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.119.010249
– ident: CR44
– volume: 65
  start-page: 440
  year: 2012
  end-page: 446
  ident: CR33
  article-title: Role of cardiac scintigraphy with mTc-DPD in the differentiation of cardiac amyloidosis subtype
  publication-title: Rev Esp Cardiol
– volume: 26
  start-page: 497
  year: 2019
  end-page: 504
  ident: CR38
  article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-017-0922-z
– volume: 27
  start-page: 1802
  year: 2020
  end-page: 1807
  ident: CR42
  article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-020-02139-8
– volume: 62
  start-page: 716
  year: 2021
  end-page: 722
  ident: CR25
  article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.120.247312
– volume: 13
  start-page: 1353
  year: 2020
  end-page: 1363
  ident: CR28
  article-title: DPD quantification in cardiac amyloidosis
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.03.020
– volume: 15
  start-page: 179
  year: 2020
  ident: CR4
  article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
  publication-title: J Rare Dis
– volume: 14
  year: 2021
  ident: CR5
  article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging
  publication-title: Circ Cardiovasc Imaging
– volume: 327
  start-page: 557
  year: 2003
  end-page: 560
  ident: CR14
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
– volume: 139
  start-page: 431
  year: 2019
  end-page: 443
  ident: CR17
  article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.118.035831
– volume: 6
  start-page: 195
  year: 2013
  end-page: 201
  ident: CR34
  article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.112.000132
– ident: CR24
– volume: 36
  start-page: 322
  year: 2020
  end-page: 334
  ident: CR1
  article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2019.12.034
– volume: 37
  start-page: 1826
  year: 2015
  end-page: 1834
  ident: CR21
  article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehv583
– volume: 139
  start-page: 431
  year: 2019
  ident: 10.1007/s12350-023-03297-1_bib17
  article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.118.035831
– volume: 13
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib41
  article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.119.010249
– volume: 6
  start-page: 195
  year: 2013
  ident: 10.1007/s12350-023-03297-1_bib34
  article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.112.000132
– ident: 10.1007/s12350-023-03297-1_bib46
  doi: 10.1007/s11604-022-01364-0
– volume: 133
  start-page: 2404
  year: 2016
  ident: 10.1007/s12350-023-03297-1_bib7
  article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.116.021612
– volume: 7
  start-page: 709
  year: 2019
  ident: 10.1007/s12350-023-03297-1_bib20
  article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice
  publication-title: JACC Heart Fail
  doi: 10.1016/j.jchf.2019.04.010
– volume: 6
  start-page: 195
  year: 2013
  ident: 10.1007/s12350-023-03297-1_bib11
  article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.112.000132
– volume: 14
  start-page: 189
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib31
  article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.07.043
– volume: 13
  start-page: 1368
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib12
  article-title: How to image cardiac amyloidosis: a practical approach
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2019.07.015
– volume: 22
  start-page: 210
  year: 2015
  ident: 10.1007/s12350-023-03297-1_bib36
  article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis
  publication-title: Amyloid
  doi: 10.3109/13506129.2015.1072089
– volume: 36
  start-page: 322
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib1
  article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2019.12.034
– volume: 2
  start-page: 17
  year: 2018
  ident: 10.1007/s12350-023-03297-1_bib29
  article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population
  publication-title: Eur J Hybrid Imaging
  doi: 10.1186/s41824-018-0035-1
– volume: 1
  start-page: 880
  year: 2016
  ident: 10.1007/s12350-023-03297-1_bib15
  article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2016.2839
– volume: 46
  start-page: 1076
  year: 2005
  ident: 10.1007/s12350-023-03297-1_bib10
  article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2005.05.073
– volume: 9
  start-page: 211
  year: 2009
  ident: 10.1007/s12350-023-03297-1_bib16
  article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression
  publication-title: STATA J
  doi: 10.1177/1536867X0900900203
– volume: 14
  start-page: 1221
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib9
  article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.08.027
– volume: 11
  start-page: 86
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib26
  article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis
  publication-title: EJNMMI Res
  doi: 10.1186/s13550-021-00828-0
– volume: 379
  start-page: 1007
  year: 2018
  ident: 10.1007/s12350-023-03297-1_bib3
  article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1805689
– volume: 27
  start-page: 28
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib43
  article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01753-5
– ident: 10.1007/s12350-023-03297-1_bib23
  doi: 10.1007/s12350-021-02563-4
– volume: 38
  start-page: 470
  year: 2011
  ident: 10.1007/s12350-023-03297-1_bib32
  article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-010-1642-7
– volume: 27
  start-page: 371
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib40
  article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01831-8
– volume: 62
  start-page: 716
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib25
  article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.120.247312
– ident: 10.1007/s12350-023-03297-1_bib44
  doi: 10.1007/s12350-022-03180-5
– volume: 14
  start-page: 1221
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib19
  article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate
  publication-title: JACC
– volume: 25
  start-page: 181
  year: 2018
  ident: 10.1007/s12350-023-03297-1_bib18
  article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-016-0610-4
– volume: 65
  start-page: 440
  year: 2012
  ident: 10.1007/s12350-023-03297-1_bib33
  article-title: Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype
  publication-title: Rev Esp Cardiol
  doi: 10.1016/j.recesp.2011.12.015
– ident: 10.1007/s12350-023-03297-1_bib22
  doi: 10.1007/s12350-021-02857-7
– ident: 10.1007/s12350-023-03297-1_bib24
  doi: 10.1016/S0735-1097(21)02708-X
– volume: 14
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib5
  article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging
  publication-title: Circ Cardiovasc Imaging
– volume: 28
  start-page: 90
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib39
  article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-019-01643-w
– volume: 37
  start-page: 1826
  year: 2015
  ident: 10.1007/s12350-023-03297-1_bib21
  article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehv583
– volume: 26
  start-page: 497
  year: 2019
  ident: 10.1007/s12350-023-03297-1_bib38
  article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-017-0922-z
– volume: 12
  year: 2019
  ident: 10.1007/s12350-023-03297-1_bib8
  article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis
  publication-title: Circ Heart Fail
  doi: 10.1161/CIRCHEARTFAILURE.119.006075
– ident: 10.1007/s12350-023-03297-1_bib6
  doi: 10.2967/jnumed.122.264311
– volume: 13
  start-page: 1353
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib28
  article-title: DPD quantification in cardiac amyloidosis
  publication-title: JACC Cardiovasc Imaging
  doi: 10.1016/j.jcmg.2020.03.020
– ident: 10.1007/s12350-023-03297-1_bib30
  doi: 10.1007/s12350-021-02880-8
– volume: 26
  start-page: 1183
  year: 2017
  ident: 10.1007/s12350-023-03297-1_bib37
  article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis
  publication-title: Heart Lung Circ
  doi: 10.1016/j.hlc.2016.12.017
– ident: 10.1007/s12350-023-03297-1_bib27
  doi: 10.1186/s40658-020-00342-7
– volume: 42
  start-page: 1554
  year: 2021
  ident: 10.1007/s12350-023-03297-1_bib2
  article-title: Diagnosis and treatment of cardiac amyloidosis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab072
– volume: 327
  start-page: 557
  year: 2003
  ident: 10.1007/s12350-023-03297-1_bib14
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
– volume: 30
  start-page: 101
  year: 2023
  ident: 10.1007/s12350-023-03297-1_bib45
  article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-022-02960-3
– volume: 155
  start-page: 529
  year: 2011
  ident: 10.1007/s12350-023-03297-1_bib13
  article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-155-8-201110180-00009
– volume: 15
  start-page: 1289
  year: 2014
  ident: 10.1007/s12350-023-03297-1_bib35
  article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis
  publication-title: Eur Heart J Cardiovasc Imaging
  doi: 10.1093/ehjci/jeu107
– volume: 15
  start-page: 179
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib4
  article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
  publication-title: J Rare Dis
– volume: 27
  start-page: 1802
  year: 2020
  ident: 10.1007/s12350-023-03297-1_bib42
  article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT
  publication-title: J Nucl Cardiol
  doi: 10.1007/s12350-020-02139-8
SSID ssj0009399
Score 2.4742794
SecondaryResourceType review_article
Snippet Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy...
Background Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the...
BackgroundBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the...
SourceID proquest
pubmed
crossref
springer
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2464
SubjectTerms Accuracy
Amyloid heart disease
Amyloid Neuropathies, Familial - diagnostic imaging
Amyloidosis
Cardiology
Cardiomyopathies - diagnostic imaging
Humans
Imaging
Medical diagnosis
Medicine
Medicine & Public Health
Meta analysis
Nuclear Medicine
Original Article
Prealbumin
Quantitative analysis
Radiology
Radionuclide Imaging
Scintigraphy
SPECT
Systematic review
Tomography, X-Ray Computed
Title Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis
URI https://dx.doi.org/10.1007/s12350-023-03297-1
https://link.springer.com/article/10.1007/s12350-023-03297-1
https://www.ncbi.nlm.nih.gov/pubmed/37226006
https://www.proquest.com/docview/2894439024
https://www.proquest.com/docview/2819276538
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1532-6551
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0009399
  issn: 1071-3581
  databaseCode: AKRWK
  dateStart: 19950101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1532-6551
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009399
  issn: 1071-3581
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1532-6551
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009399
  issn: 1071-3581
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1532-6551
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0009399
  issn: 1071-3581
  databaseCode: U2A
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVkJcKG9SyspI3MBVYidxwm1Lu1Sg9sRK5WT5FWlFN0Hd7KHw5xknzkaiD6nKJYrtaOLMeGY0M98AfNAs0ZY7Q4VvHYAar6Kly1NqBIudzbjWHWT-6Vl-ski_nWfnoShsPWS7DyHJ7qQei90Yz2KKOobGnJWCos-zk3kHZQI7s68_vx-PYLu86xuJnk1CPb5XKJa5-S23KaTrBue1YGmng-a7sBio71NPfh1sWn1g_vwH7Hjfz3sKT4JRSmY9Fz2DB65-Do9OQ9j9Bfw96hPycJgoYzaXylyRpiK6qR1BHVq3yx74mixXXdcjgqYwab0aRD7wdZI1MR0r4vrV1UWztM16uf5MRhxp0tfQEFVbsnKtoiqgpbyExfz4x5cTGro2UIOuTEttZXOh0Q-JqyIvWKUsXvigjDWr0sLGaaJT5VFteKGKJK3KItbopJu8KpLcWf4KJjWS_waI46lRLtO85HhX5qV1ieFMC6OFLoSJIBl-nTQB0tx31riQIxiz31WJuyq7XZVJBB-3a373gB53zs4GjpDBJOlNDYka5851-wP7yHAorCX6tilKA1pFEbzfDqM4-xiNql2z8XPQ5BY5qqEIXvdstyWTC-bbCeQRfBpYaHz57bTs3W_6W3jMPBd2KTv7MGkvN-4dGl6tnqKczQ8Pz6ZB3qbwcMFm_wCRcySS
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6hrQRceFNSChiJG7hKYidxuFXQstBuT12pnCy_Iq3oJqibPbT8ecaJs5EorVTlEsV2NHHG_mY0nm8APug00ZY5QwtfOgARr6Klyzk1RRo7mzGtO8r82Uk-nfMfZ9lZSApbDafdh5Bkt1OPyW4py2KKGENjlpYFRZ9niydC8Als7X_7eXQwku2yrm4kejYJ9fxeIVnm_2-5CZCuG5zXgqUdBh0-hvkgfX_05NfeutV75uofYse7ft4TeBSMUrLfa9FTuOfqZ3B_FsLuz-HP1_5AHjYTZcz6QplL0lREN7UjiKF1u-iJr8li2VU9ImgKk9bDIOqBz5OsielUEccvL8-bhW1Wi9VnMvJIkz6HhqjakqVrFVWBLeUFzA8PTr9MaajaQA26Mi21lc0LjX5IXIlcpJWyeOGDMtZpxYWNeaK58qw2TCiR8KoUsUYn3eSVSHJn2UuY1Cj-KyCOcaNcplnJ8K7MS-sSw1JdGF1oUZgIkuHXSRMozX1ljXM5kjH7WZU4q7KbVZlE8HEz5ndP6HFr72zQCBlMkt7UkIg4t47bHdRHhk1hJdG35bga0CqK4P2mGZezj9Go2jVr3wdN7iJHGIpgu1e7jZisSH05gTyCT4MKjS-_WZadu3V_Bw-mp7Njefz95Og1PEy9RnbHd3Zh0l6s3Rs0wlr9Nqy5v3XDJR4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYlhdBLSdO0dZomKvTWitiSLNm9hSZLHk3IoQu5CT1hIesNWe-h9M93JNvrQppA8MVYD4RnxPcN0nyD0BdDC-OYt0TG0gGAeIHUXnBiJc29K5kxSTL_8kqcTvn5TXnzTxZ_uu0-HEl2OQ1RpalpD-9cOBwT3ygrcwJ4Q3JGa0kg_nnJAatj-DWlR6PsLksVJCHGKUhU-urTZv4_x2PQ9JB6Pjg2TWg02UKvexqJjzq7v0EvfLONNi_7g_K36M9xd4UOmrG2dnWv7W-8CNgsGo8B9Zp21klV49k81SnCQF5xG4ELLBczGxtsk_PA-DkE9TO3WM6W3_Go_Iy7rBesG4fnvtVE9_omO2g6Ofn145T0dRaIheCjJS44IQ1EDnmoREWDdvDAhzo3NPDK5bwwXEcdGlbpquChrnIDYbUVoSqEd-wd2mhg-R8Q9oxb7UvDagZvtaidLyyjRlojTSVthorhFyvbi5DHWhi3apRPjmZRYBaVzKKKDH1dj7nrJDie7F0OllM9iejIgQKMeHLc3mBm1W_jpYJolIP_Ao_J0Od1M2zAeKqiG79YxT5AkqUA4MjQ-8491stkksYCACJD3wZ_GSd_fC27z-t-gDavjyfq59nVxUf0ikaPTvdt9tBGe7_yn4A1tWY_bYy_KMAMbA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+accuracy+of+bone+scintigraphy+imaging+for+transthyretin+cardiac+amyloidosis%3A+systematic+review+and+meta-analysis&rft.jtitle=Journal+of+nuclear+cardiology&rft.au=Ahluwalia%2C+Nanki&rft.au=Roshankar%2C+Golnaz&rft.au=Draycott%2C+Logan&rft.au=Jimenez-Zepeda%2C+Victor&rft.date=2023-12-01&rft.eissn=1532-6551&rft.volume=30&rft.issue=6&rft.spage=2464&rft_id=info:doi/10.1007%2Fs12350-023-03297-1&rft_id=info%3Apmid%2F37226006&rft.externalDocID=37226006
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-3581&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-3581&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-3581&client=summon